A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer

Maria Gabriella Ferrandina, Giovanni Scambia, Giuseppina Raspaglio, Flavia Filippetti, Marco Petrillo, Marianna Buttarelli, Gabriele Babini, Alessandra Battaglia, Alessandra Ciucci, Carmela Marino, Mariateresa Mancuso, Anna Saran, Maria Elena Villani, Angiola Desiderio, Chiara D'Ambrosio, Andrea Scaloni, Daniela Gallo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)

Abstract

A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer. BACKGROUND: A better understanding of locally advanced cervical cancer (LACC) is mandatory for further improving the rates of disease control, since a significant proportion of patients still fail to respond or undergo relapse after concurrent chemoradiation treatment (CRT), and survival for these patients has generally remained poor. METHODS: To identify specific markers of CRT response, we compared pretreatment biopsies from LACC patients with pathological complete response (sensitive) with those from patients showing macroscopic residual tumor (resistant) after neoadjuvant CRT, using a proteomic approach integrated with gene expression profiling. The study of the underpinning mechanisms of chemoradiation response was carried out through in vitro models of cervical cancer. RESULTS: We identified annexin A2 (ANXA2), N-myc downstream regulated gene 1 (NDRG1) and signal transducer and activator of transcription 1 (STAT1) as biomarkers of LACC patients' responsiveness to CRT. The dataset collected through qPCR on these genes was used as training dataset to implement a Random Forest algorithm able to predict the response of new patients to this treatment. Mechanistic investigations demonstrated the key role of the identified genes in the balance between death and survival of tumor cells. CONCLUSIONS: Our results define a predictive gene signature that can help in cervical cancer patient stratification, thus providing a useful tool towards more personalized treatment modalities.
Lingua originaleEnglish
pagine (da-a)279-N/A
RivistaJOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume38
DOI
Stato di pubblicazionePubblicato - 2019

Keywords

  • Cervix
  • LACC
  • Molecular biomarkers
  • Personalized medicine
  • Proteomics

Fingerprint Entra nei temi di ricerca di 'A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer'. Insieme formano una fingerprint unica.

Cita questo